The Use of Platelet-Rich Plasma in Osteoarthritis and Fractures

Akhil Gollapudi

doi:10.37022/jis.v7i2.86

Gollapudi Akhil Priyadarshini Institute of pharmaceutical Education and Research, 5th Mile, Pulladigunta, Guntur -522017, Andhra Pradesh, India.

DOI https://doi.org/10.37022/jis.v7i2.86

Abstract

In order to promote and enhance bone healing, biologic drugs have been studied and used recently. Plasmon rich plasma, or PRP, is one of these substances that is becoming more and more popular as an emerging tactic. Examining the available research on PRP injection use and clinical efficacy—particularly with regard to treating non-union fractures—is the primary goal of this study. Recent Discoveries Even though level IV evidence predominated, most published research claimed that PRP sped up the healing of fractures. Currently impeding the successful clinical translation of platelet-rich plasma (PRP) as a therapy for non-union fractures is the absence of randomized, clinical trials (level I–II evidence). Its ability to cure non-union fractures, either on its own or in conjunction with other therapies, has been reported to be promising. Entire text The effects of delivering larger volumes of PRP (i.e., 5–20 mL) and the necessity of longer (> 11 months) randomised clinical trials are two future recommendations that should help accelerate clinical translation and adoption of PRP as a therapeutic.minimum negative consequences.

Keywords: Bone healing, Fracture, Non-union, Platelet-rich plasma (PRP)

References

1. Landrino M, Alberio RL, Clemente A, Grassi FA. The Reamer-Irrigator-Aspirator (RIA) System for the treatment of aseptic femoral nonunions: Report of two cases and literature review. Orthopedic Reviews. 2022;14(4).
2. Ferreira N, Marais LC, Aldous C. Challenges and controversies in defining and classifying tibial non-unions. SA Orthopaedic Journal. 2014 Aug;13(2):52-6. http://www.scielo.org.za/scielo.php?script=sci_arttext&pid=S1681-150X2014000200007
3. Panagiotis M. Classification of non-union. Injury. 2005 Nov 1;36(4): S30-7.
4. Mogili R, Kanala K, Bannoth CK, Chandu BR, Challa BR. Quantification of esomeprazole in human plasma by liquid chromatography tandem mass spectrometry and its application to bioequivalence study. Der Pharm Lett. 2011;3(5):138-45.
5. Kanala K, Hwisa NT, Chandu BR, Assaleh FH, Mukkanti K, Katakam P, Challa BS. Simultaneous quantification of mesalamine and its metabolite N-acetyl mesalamine in human plasma by LC-MS/MS and its application to a bioequivalence study. British Journal of Pharmaceutical Research. 2014 Jul 1;4(13):1568.
6. O’Connell B, Wragg NM, Wilson SL. The use of PRP injections in the management of knee osteoarthritis. Cell and tissue research. 2019 May 6;376:143-52.
7. Menon RS, Wragg NM, Wilson SL. Rotator cuff repair augmentation using osteoinductive growth factors. SN Comprehensive Clinical Medicine. 2019 Apr 15;1:267-76.
8. Dickinson M, Wilson SL. A critical review of regenerative therapies for shoulder rotator cuff injuries. SN Comprehensive Clinical Medicine. 2019 Mar;1(3):205-14.
9. Mogili R, Kanala K, Challa BR, Chandu BR, Bannoth CK. Determination of rizatriptan in human plasma by liquid chromatography stable isotope dilution electrospray MS–MS for application in bioequivalence study. Chromatographic. 2011 Oct; 74:585-92.
10. Galasso O, Mariconda M, Romano G, Capuano N, Romano L, Ianno B, Milano C. Expandable intramedullary nailing and platelet rich plasma to treat long bone non-unions. Journal of Orthopedics and Traumatology. 2008 Sep; 9:129-34.
11. Bielecki T, Gazdzik TS, Szczepanski T. Benefit of percutaneous injection of autologous platelet-leukocyte-rich gel in patients with delayed union and nonunion. European Surgical Research. 2008 Feb 15;40(3):289-96.
12. Chiang ER, Ma HL, Wang JP, Liu CL, Chen TH, Hung SC. Allogeneic mesenchymal stem cells in combination with hyaluronic acid for the treatment of osteoarthritis in rabbits. PloS one. 2016 Feb 25;11(2):e0149835.
13. Mogili R, Kanala K, Challa BR, Chandu BR, Bannoth CK. Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study. Scientia Pharmaceutica. 2011 Sep;79(3):583-600.
14. Kumar KR, Nagaraju GV, Subrahmanyam SN, Nagarani K, Shareef S, Tennygilphin M, Namballa M. Assessment on Elements Involving the Academic Performance among Pharmacy Students: A Cross-Sectional Observational Study. Int J Cur Res Rev| Vol. 2021 Dec;13(23):141.
15. Tarallo L, Mugnai R, Adani R, Catani F. Treatment of the ulna non-unions using dynamic compression plate fixation, iliac bone grafting and autologous platelet concentrate. European Journal of Orthopaedic Surgery & Traumatology. 2012 Dec;22:681-7.
16. Sánchez AR, Sheridan PJ, Kupp LI. Is platelet-rich plasma the perfect enhancement factor? A current review. International Journal of Oral & Maxillofacial Implants. 2003 Jan 1;18(1).
17. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. Jama. 2018 Oct 2;320(13):1360-72.
18. Voshaar M, Vriezekolk J, van Dulmen S, van den Bemt B, Van De Laar M. Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC musculoskeletal disorders. 2016 Dec; 17:1-2.
19. Bielecki T, Gazdzik TS, Szczepanski T. Benefit of percutaneous injection of autologous platelet-leukocyte-rich gel in patients with delayed union and nonunion. European Surgical Research. 2008 Feb 15;40(3):289-96.
20. Ferreira N, Marais LC, Aldous C. Challenges and controversies in defining and classifying tibial non-unions. SA Orthopaedic Journal. 2014 Aug;13(2):52-6.